SCHEMBL21595503

SCHEMBL21595503

CS/C(=N\c1ccccc1F)c1cccc(C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.43
P2RX7 Q99572 1/20 0.36
GRM5 P41594 1/20 0.35
CTH P32929 1/20 0.34
KMT2A Q03164 4/20 0.33
CNR2 P34972 1/20 0.33
HKDC1 Q2TB90 1/20 0.33
MEN1 O00255 3/20 0.32
CCR1 P32246 1/20 0.32
CCR8 P51685 1/20 0.32
DUSP3 P51452 1/20 0.32
PTPN11 Q06124 1/20 0.32
MAPT P10636 4/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
CA9 Q16790 1/20 0.32
MITF O75030 1/20 0.32
MAPK1 P28482 1/20 0.32
MDM2 Q00987 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21595505 1.00 HSP90AA1 (0.43) HSP90AA1P2RX7GRM5CTHKMT2A
SCHEMBL20302248 0.82 HSP90AA1 (0.43) HSP90AA1P2RX7GRM5CTHCNR2
SCHEMBL20302249 0.82 HSP90AA1 (0.43) HSP90AA1P2RX7GRM5CTHCNR2
SCHEMBL21595541 0.81 KDM4E (0.44) CTHKMT2AMEN1MAPTNPSR1
SCHEMBL21595540 0.81 KDM4E (0.44) CTHKMT2AMEN1MAPTNPSR1
SCHEMBL21595593 0.74 KMT2A (0.44) KMT2ACNR2MEN1MAPTCA1
SCHEMBL21595525 0.74 SMN1; SMN2 (0.40) MAPTNPC1RAB9ATP53HTT
SCHEMBL21595524 0.74 SMN1; SMN2 (0.40) MAPTNPC1RAB9ATP53HTT
SCHEMBL20302205 0.74 P2RX7 (0.33) HSP90AA1P2RX7CTHHKDC1CA1
SCHEMBL20302204 0.74 P2RX7 (0.33) HSP90AA1P2RX7CTHHKDC1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810597-B1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS UNIV OSLO HF (NO) 2025-11-26 EP disclosed
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors OSLO UNIVERSITETSSYKEHUS HF (NO) 2024-03-12 US disclosed
EP-3810597-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS Oslo Universitetssykehus HF (NO) 2021-04-28 EP disclosed
WO-2019243822-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS OSLO UNIVERSITETSSYKEHUS HF (NO) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors GBA3, CBR3, TECR HSP90AA1 3890/4885P2RX7 3066/4885GRM5 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.